1H-苯并咪唑-4-甲胺 | 64574-24-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1H-苯并咪唑-4-甲胺
• 英文名称: (1H-benzo[d]imidazol-4-yl)methanamine
• 英文别名: C-(1(3)H-benzoimidazol-4-yl)-methylamine；4-Aminomethyl-benzimidazol；1H-benzimidazol-4-ylmethanamine
• CAS: 64574-24-9
• 化学式: C₈H₉N₃
• 分子量: 147.18
• InChiKey: HNANBZSSHVTMEU-UHFFFAOYSA-N

物化性质

• 沸点：
  432.8±20.0 °C(Predicted)
• 密度：
  1.278±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1H-苯并咪唑-4-甲胺 以89%的产率得到
  参考文献：
  名称：

  LEBENSTEDT E.; SCHUNACK W., ARCH. PHARM. , 1977, 310, NO 6, 455-460

  摘要：

  DOI：
• 作为产物：
  描述：

  (9ci)-1H-苯并咪唑-4-甲腈 以73%的产率得到
  参考文献：
  名称：

  LEBENSTEDT E.; SCHUNACK W., ARCH. PHARM. , 1977, 310, NO 6, 455-460

  摘要：

  DOI：

文献信息

• Discovery of aminoquinazoline derivatives as human A2A adenosine receptor antagonists
  作者：Gang Zhou、Robert Aslanian、Gioconda Gallo、Tanweer Khan、Rongze Kuang、Biju Purakkattle、Manuel De Ruiz、Andrew Stamford、Pauline Ting、Heping Wu、Hongwu Wang、Dong Xiao、Tao Yu、Yonglian Zhang、Deborra Mullins、Robert Hodgson

  DOI：10.1016/j.bmcl.2015.11.048

  日期：2016.2

  adenosine A(2A) antagonists with an aminoquinazoline moiety were designed and synthesized. The optimization of the initial lead compound based on in vitro and in vivo activity has led to the discovery of a potent and selective class of adenosine A(2A) antagonists. The structure-activity relationships of this novel series of bicyclic aminoquinazoline derivatives as adenosine A(2A) antagonists are described

  设计并合成了具有氨基喹唑啉部分的新型双环腺苷A（2A）拮抗剂。基于体外和体内活性的初始先导化合物的优化已导致发现一种有效且选择性的腺苷A（2A）拮抗剂。详细介绍了该新型系列的双环氨基喹唑啉衍生物作为腺苷A（2A）拮抗剂的结构活性关系。
• Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT2A receptor antagonists/inverse agonists
  作者：Mingxu Ma、Yifei Yang、Guangying Du、Yusen Dai、Xiaoyin Zhu、Wenyan Wang、Hengwei Xu、Jianzhao Zhang、Lixia Zheng、Fangxia Zou、Huijie Yang、Bin Liu、Wanhui Liu、Liang Ye、Rui Zhang、Jingwei Tian

  DOI：10.1016/j.ejmech.2022.114246

  日期：2022.4

  series of novel pimavanserin derivatives (7–1∼7–37) were designed and synthesized. The biological activities were evaluated by cell assays and compound 7–16 exhibited 50-fold higher 5-HT2A receptor antagonist activity (IC50 = 0.54 vs 27.3 nM) and 23-fold higher inverse agonist activity (IC50 = 2.1 vs 50 nM) than pimavanserin. Moreover, 7–16 showed increased potency window between the 5-HT2A and hERG

  Pimavanserin是FDA于2016年批准的选择性5-HT 2A受体拮抗剂和反向激动剂，用于治疗帕金森病精神病（PDP）患者。但匹马万色林具有潜在风险，会增加老年患者的死亡率，也会增加患者 QT 间期延长的风险。因此，迫切需要寻找高效、低毒的新药。基于匹马范色林的对接研究，设计合成了一系列新型匹马范色林衍生物（ 7-1∼7-37 ）。通过细胞试验评估了生物活性，化合物7 – 16的 5-HT 表现出高 50 倍2A受体拮抗剂活性（IC 50  = 0.54 vs 27.3 nM）和反向激动剂活性（IC 50  = 2.1 vs 50 nM）是匹马万色林的 23 倍。此外，7 - 16显示 5-HT2A 和 hERG 活性之间的效力窗口比匹马万色林增加。此外，化合物7-16表现出优异的体外和体内药代动力学，体内功能活性提高了4倍，并且具有良好的安全性。因此，化合物7 – 16代表了一种
• Engineering Fluorophore Recycling in a Fluorogenic RNA Aptamer
  作者：Xing Li、Jiahui Wu、Samie R. Jaffrey

  DOI：10.1002/anie.202108338

  日期：2021.11.2

  Fluorogenic RNA aptamers bind to and activate the fluorescence of otherwise nonfluorescent dyes. Here we show an approach to maximize their fluorescence by reducing the impact of photobleaching. We engineered TBI, a fluorophore that rapidly dissociates upon photobleaching and can be rapidly replaced by TBI in the media. By maximizing “fluorophore recycling”, we achieve higher fluorescence and enable

  荧光 RNA 适体结合并激活其他非荧光染料的荧光。在这里，我们展示了一种通过减少光漂白的影响来最大化其荧光的方法。我们设计了 TBI，这是一种在光漂白后迅速解离的荧光团，并且可以在培养基中快速被 TBI 取代。通过最大化“荧光团回收”，我们实现了更高的荧光并实现长期荧光成像。
• INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR MEDIATING OR INHIBITING CELL PROLIFERATION
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：EP1250326A2

  公开（公告）日：2002-10-23
• [EN] INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR MEDIATING OR INHIBITING CELL PROLIFERATION<br/>[FR] COMPOSES D'INDAZOLE, COMPOSITIONS PHARMACEUTIQUES, ET METHODES DESTINES A LA MEDIATION OU A L'INHIBITION DE LA PROLIFERATION CELLULAIRE
  申请人：AGOURON PHARMA

  公开号：WO2001053268A2

  公开（公告）日：2001-07-26

  Indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating , e.g., kinases-dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.